semaglutide
Semaglutide Isn't What You Were Told vs Tirzepatide
A 30% price hike for patients is the first tangible impact of the FDA’s 2026 exclusion of semaglutide, tirzepatide and liraglutide from the 503B bulk list. The rule forces virtual weight-loss clinics to abandon low-cost compounded supplies and switch to pricier 503A prescriptions, delaying care for remote users. Medical